Atovaquone: meta-analysis of COVID-19 studies

All studies   Mortality   Hospitalization   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
Meta-analysis1 study · 60 patientsc19early.org

Atovaquone for COVID-19

Serious outcome risk
Atovaquone
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−39%
Mortality (1)−39%
Hospitalization (1)16%
RCTs (1)−39%
Late (1)−39%
00.511.5+
← Atovaquone
reduces riskIncreased
risk →
c19early.org
October 2026

Atovaquone COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Jain (DB RCT)−39%1.39 · 0.31–6.26death6/412/19
Late treatment−39%1.39 · 0.31–6.266/412/1939% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.68
All studies−39%1.39 · 0.31–6.266/412/1939% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6800.511.52+
Rotate screen for more detailsIncrease width for more details
← Atovaquone
reduces riskAtovaquone
increases risk →
c19early.org
October 2026

Atovaquone COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Jain (DB RCT)−39%1.39 · 0.31–6.266/412/19
Late treatment−39%1.39 · 0.31–6.266/412/1939% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.68
All studies−39%1.39 · 0.31–6.266/412/1939% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6800.511.52+
Rotate screen for more detailsIncrease width for more details
← Atovaquone
reduces riskAtovaquone
increases risk →
c19early.org
October 2026

Atovaquone COVID-19 hospitalization results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Jain (DB RCT)16%0.84 · 0.70–1.01hosp. time41 (n)19 (n)
Late treatment16%0.84 · 0.70–1.0141 (n)19 (n)16% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.069
All studies16%0.84 · 0.70–1.0141 (n)19 (n)16% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.06900.511.52+
Rotate screen for more detailsIncrease width for more details
← Atovaquone
reduces riskAtovaquone
increases risk →
c19early.org
October 2026

Atovaquone COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Jain (DB RCT)−39%1.39 · 0.31–6.26death6/412/19
Late treatment−39%1.39 · 0.31–6.266/412/1939% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.68
All studies−39%1.39 · 0.31–6.266/412/1939% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6800.511.52+
Rotate screen for more detailsIncrease width for more details
← Atovaquone
reduces riskAtovaquone
increases risk →
c19early.org
October 2026

Atovaquone COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Jain (DB RCT)−39%1.39 · 0.31–6.26death6/412/19
Late treatment−39%1.39 · 0.31–6.266/412/1939% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.68
All studies−39%1.39 · 0.31–6.266/412/1939% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6800.511.52+
Rotate screen for more detailsIncrease width for more details
← Atovaquone
reduces riskAtovaquone
increases risk →
c19early.org
October 2026

Atovaquone COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Jain (DB RCT)−39%1.39 · 0.31–6.266/412/19
Late treatment−39%1.39 · 0.31–6.266/412/1939% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.68
All studies−39%1.39 · 0.31–6.266/412/1939% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6800.511.52+
Rotate screen for more detailsIncrease width for more details
← Atovaquone
reduces riskAtovaquone
increases risk →
c19early.org
October 2026

Atovaquone COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Jain (DB RCT)−39%1.39 · 0.31–6.26death6/412/19
Late treatment−39%1.39 · 0.31–6.266/412/1939% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.68
All studies−39%1.39 · 0.31–6.266/412/1939% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6800.511.52+
Rotate screen for more detailsIncrease width for more details
← Atovaquone
reduces riskAtovaquone
increases risk →